BIOMAT Database Logo BIOMAT Database Logo

Preformed lymphocytotoxic antibodies: the effects of class, titer and specificity on liver vs. heart allografts. 1992

T Furuya, and N Murase, and K Nakamura, and J Woo, and S Todo, and A J Demetris, and T E Starzl
Pittsburgh Transplant Institute, Department of Surgery, University of Pittsburgh, Pennsylvania 15261.

The effect on liver and heart allograft survival (ACI rats to Lewis rats) was studied after three methods of recipient presensitization and after different intervals between sensitization and transplantation. With comparable lymphocytotoxic antibody titers, liver allografts always survived longer than heart grafts. The titer, class and specificity of the antibodies varied with the method of sensitization. Four skin grafts produced IgG and IgM lymphocytotoxic antibody titers of 1:2,000 to 4,000. The IgG fraction was shown to have hepatic vascular endothelial specificity by indirect immunofluorescence. These primed recipients hyperacutely rejected both heart and liver allografts, which showed vascular deposition of IgG antibodies. Survival of either kind of graft was inversely proportional to the lymphocytotoxic antibody titer and length of time after placement of the last skin graft. Presensitization with a single heterotopic heart graft produced an even higher mixed IgG and IgM lymphocytotoxic antibody titer of 1:8,000 but with less IgG vascular endothelial specificity. These animals also hyperacutely rejected heart or liver grafts with tissue deposition of IgG but less consistently and with a weaker correlation with lymphocytotoxic antibody titers and time after sensitization. Sensitization with two pretransplant blood transfusions produced the lowest titer (1:500 to 1,000) and the least IgG vascular endothelial specificity. Liver allograft survival was routinely enhanced in these animals, and little effect was seen on heart grafts. Collectively, the experiments showed that the liver is not only resistant to antibody-mediated rejection relative to the heart but is more easily enhanced.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007075 Immunoglobulin M A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally was called a macroglobulin. Gamma Globulin, 19S,IgM,IgM Antibody,IgM1,IgM2,19S Gamma Globulin,Antibody, IgM
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D008297 Male Males
D011912 Rats, Inbred ACI An inbred strain of rat that is widely used in BIOMEDICAL RESEARCH. Applications include the study of spontaneous NEOPLASMS; CHRONIC KIDNEY DISEASES, and CONGENITAL ABNORMALITIES. Rats, Inbred A x C 9935 Irish,Rats, ACI,ACI Rat,ACI Rat, Inbred,ACI Rats,ACI Rats, Inbred,Inbred ACI Rat,Inbred ACI Rats,Rat, ACI,Rat, Inbred ACI
D011917 Rats, Inbred Lew An inbred strain of rat that is used in BIOMEDICAL RESEARCH. Rats, Inbred Lewis,Rats, Lew,Inbred Lew Rat,Inbred Lew Rats,Inbred Lewis Rats,Lew Rat,Lew Rat, Inbred,Lew Rats,Lew Rats, Inbred,Lewis Rats, Inbred,Rat, Inbred Lew,Rat, Lew
D001803 Blood Transfusion The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed) Blood Transfusions,Transfusion, Blood,Transfusions, Blood
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft

Related Publications

T Furuya, and N Murase, and K Nakamura, and J Woo, and S Todo, and A J Demetris, and T E Starzl
A clinicopathologic study of isolated intestinal allografts with preformed IgG lymphocytotoxic antibodies.
May 2002, Transplantation proceedings,
T Furuya, and N Murase, and K Nakamura, and J Woo, and S Todo, and A J Demetris, and T E Starzl
A clinicopathologic study of isolated intestinal allografts with preformed IgG lymphocytotoxic antibodies.
November 2004, Human pathology,
T Furuya, and N Murase, and K Nakamura, and J Woo, and S Todo, and A J Demetris, and T E Starzl
Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies.
January 1994, Transplant immunology,
T Furuya, and N Murase, and K Nakamura, and J Woo, and S Todo, and A J Demetris, and T E Starzl
Immunoglobulin class and specificity of lymphocytotoxic antibodies after kidney transplantation.
January 1988, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
T Furuya, and N Murase, and K Nakamura, and J Woo, and S Todo, and A J Demetris, and T E Starzl
Combined liver-kidney transplantation: analysis of patients with preformed lymphocytotoxic antibodies.
February 1988, Transplantation proceedings,
T Furuya, and N Murase, and K Nakamura, and J Woo, and S Todo, and A J Demetris, and T E Starzl
Preformed lymphocytotoxic antibodies disappear following cyclosporine therapy.
May 1985, The Journal of heart transplantation,
T Furuya, and N Murase, and K Nakamura, and J Woo, and S Todo, and A J Demetris, and T E Starzl
A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies.
September 1992, Hepatology (Baltimore, Md.),
T Furuya, and N Murase, and K Nakamura, and J Woo, and S Todo, and A J Demetris, and T E Starzl
Development of class I-directed lymphocytotoxic antibodies after liver transplantation.
February 1987, Transplantation proceedings,
T Furuya, and N Murase, and K Nakamura, and J Woo, and S Todo, and A J Demetris, and T E Starzl
Preformed antibodies to biliary epithelial cells and acute rejection of liver allografts.
March 2004, Journal of hepatology,
T Furuya, and N Murase, and K Nakamura, and J Woo, and S Todo, and A J Demetris, and T E Starzl
Interactions between liver allografts and lymphocytotoxic alloantibodies in inbred rats.
January 1986, Hepatology (Baltimore, Md.),
Copied contents to your clipboard!